Logo

EMBL Becomes Customer of Amersham s CodeLink Microarray Platform

Jan 21, 2004

This update serves to clarify that Amersham has not sold its CodeLink business to EMBL, but rather a CodeLink system for internal research.

 

NEW YORK, Jan. 21 (GenomeWeb News) - Amersham Biosciences has sold a CodeLink microarray platform to the European Molecular Biology Laboratory, Amersham said today.

 

EMBL's genomics core facility in Heidelberg will offer gene-expression services based on the technology to EMBL groups and their collaborators. In addition, EMBL and Amersham will jointly organize training and access to the platform. An EMBL developmental biology research groups has already been using CodeLink microarrays to study gene expression in mice, according to Amersham.

 

According to the EMBL website, its core facility is also offering services using Affymetrix's gene expression platform.

Breaking News
The Scan

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.

Family Genetic Risk Score Linked to Diagnostic Trajectory in Psychiatric Disorders

Researchers in JAMA Psychiatry find ties between high or low family genetic risk scores and diagnostic stability or change in four major psychiatric disorders over time.

Study Questions Existence of Fetal Microbiome

A study appearing in Nature this week suggests that the reported fetal microbiome might be the result of sample contamination.

Fruit Fly Study Explores Gut Microbiome Effects on Circadian Rhythm

With gut microbiome and gene expression experiments, researchers in PNAS see signs that the microbiome contributes to circadian rhythm synchronicity and stability in fruit flies.